Street Poller Media and The Boom of the Street Interview Ad Industry 
The Realist’s Case: Lukas Kerrebijn of RD Dubai on the Narrative Dubai’s Agents Won’t Question 
Trump Administration Plans New Drug Pricing Deals With Biotech Firms 
Jefferies Names AMEC Top China Semiconductor Equipment Pick 
OpenAI AI Agent Swarm Behind Hugging Face Hack 
Nvidia Pauses AI Cloud Financing Deals Amid Antitrust Concerns 
Meta Agrees to $18 Billion Settlement, Tightens Teen Social Media Rules 
Honda, Nissan Eye Shared Vehicle Software Platform by 2029 
Nvidia Revenue Soars 106% as AI Demand Hits ‘Inflection Point’ 
Nvidia Reportedly Eyes $13 Billion Hugging Face Acquisition 
Shein Hong Kong IPO to Raise $1.7 Billion at $26.5 Billion Valuation 
Pinterest Stock Falls as CFO Julia Brau Donnelly Resigns 
Yindjibarndi Appeals Fortescue Mining Compensation Ruling 
PayPal Shares Sink as $50 Billion Takeover Bid Collapses 
Google Changes EU Spam Policy Amid Antitrust Scrutiny 
Trian Drops Wendy’s Take-Private Bid Plans, Shares Plunge 14% 
Add as a preferred source on Google
NEW YORK, April 11, 2018 -- Safirstein Metcalf LLP, announces that a class action lawsuit was filed in the U.S. District Court for the District of New Jersey on behalf of all persons or entities who purchased or otherwise acquired Cancer Genetics, Inc. (NASDAQ:CGIX) (“Cancer Genetics” or the “Company”) securities between March 23, 2017 and April 2, 2018 (the “Class Period”).
If you purchased or acquired Cancer Genetics securities during the class period, and would like more information about the shareholder class action, please contact Safirstein Metcalf LLP at 1-800-221-0015, or email [email protected]
If you wish to serve as lead plaintiff, you must move the Court no later than June 4, 2018. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice or may choose to do nothing and remain an absent class member.
According to the complaint, the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. On April 2, 2018, the Company reported that, following its CEO’s departure, it conducted a comprehensive review of its strategy and organization. This led the Company to record a bad debt expense of $4.4 million and write off $1.8 million of its accounts receivable in the fourth quarter, with a significant portion related to collection issues with accounts receivables recorded after 2015. The Company also reported that, on December 31, 2017, its “cash position and history of losses required management to assess [its] ability to continue operating as a going concern[.]” Following this news, shares of Cancer Genetics fell $0.55 per share or over 33% to close at $1.10 per share on April 3, 2018.
About Safirstein Metcalf LLP
Safirstein Metcalf LLP focuses its practice on shareholder rights. The law firm also practices in the areas of antitrust and consumer protection. All of the Firm’s legal endeavors are rooted in its core mission: provide investor and consumer protection.
Attorney advertising. Prior results do not guarantee a similar outcome.
Safirstein Metcalf LLP
Peter Safirstein, Esq.
1250 Broadway
27th Floor
New York, NY 10001
1-800-221-0015
